| Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.Eur J Cancer | PMID 36379186PMC11195534 | 2023-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Paediatr Drugs | PMID 36380186PMC9666949 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.Thromb Res | PMID 36396519PMC9657896 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase III, multi-centered, double-blind, hospital-based, randomized controlled trial.Int J Infect Dis | PMID 36400376无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial.Epilepsy Behav | PMID 36410152无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).Int J Clin Oncol | PMID 36414827无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adherence, safety and potential effectiveness of a home-based Radio-Taiso exercise program in older adults with frailty: A pilot randomized controlled trial.Geriatr Gerontol Int | PMID 36426763PMC10100027 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).Eur J Cancer | PMID 36434888无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.Epilepsy Behav | PMID 36435010无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).Eur J Cancer | PMID 36459768无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Lancet Oncol | PMID 36460017无 PMCID | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.Epilepsy Behav | PMID 36463826无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.CNS Drugs | PMID 36484969PMC9829592 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 36493792PMC11200328 | 2023-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.Am J Clin Dermatol | PMID 36512175PMC10032219 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.Paediatr Drugs | PMID 36529811PMC9810566 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.J Neurooncol | PMID 36609807PMC9886607 | 2023-Jan | 0.85 | This is a secondary analysis of hematotoxicity and its prognostic relevance from a Phase III trial. While the underlying trial is a drug-containing randomized oncology study, the specific report does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, Kaplan-Meier curves, HR for efficacy) as its main focus. The survival analysis was conducted only to explore the association of hematotoxicity with survival, not as the primary efficacy outcome. Therefore, it does not meet the criteria for inclusion. | 待处理 |
| Evaluation of the efficacy and safety of NVP-1203 and aceclofenac in patients with acute low back pain and muscle spasm: A randomized, double-blind, active-controlled, parallel, multicenter, phase 3 clinical trial.Eur Rev Med Pharmacol Sci | PMID 36647880无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.Headache | PMID 36651532PMC10107835 | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.RMD Open | PMID 36720560PMC9890804 | 2023-Jan | 1.00 | The record describes a Phase 3, randomized, placebo-controlled trial of tofacitinib for psoriatic arthritis, not a human malignant neoplasm (cancer). The primary endpoint is ACR50 response (categorical), and there is no mention of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier). | 待处理 |
| Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.Lancet Rheumatol | PMID 38251504无 PMCID | 2023-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Generalized phase I-II designs to increase long term therapeutic success rate.Pharm Stat | PMID 37038957PMC10524372 | 2023 | 0.97 | 仅有 Phase I/II 证据,未达到确证性随机试验标准。 | 待处理 |
| Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies.J Ocul Pharmacol Ther | PMID 36378864PMC9885540 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.J Med Econ | PMID 36601798无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.J Prev Alzheimers Dis | PMID 36641605无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vestibulotoxicity in Patients Undergoing Cisplatin-Based Cancer Treatment: A Phase IIIB Randomized Controlled Clinical Trial.Audiol Neurootol | PMID 36731442无 PMCID | 2023 | 0.90 | The study is an eligible Phase IIIB randomized trial with a drug intervention (dexamethasone) in cancer patients, but the primary outcome is vestibulotoxicity/safety (video head impulse test), not a time-to-event efficacy endpoint like OS, PFS, or TTP. No Kaplan-Meier or HR data are reported. | 待处理 |
| Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.Technol Cancer Res Treat | PMID 37016933PMC10084583 | 2023 | 0.95 | The record meets criteria for oncology, human, randomized, Phase III, and original result. However, it is ineligible because it lacks a drug-containing intervention (it compares radiotherapy techniques) and does not have a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan.J Neuromuscul Dis | PMID 37125562PMC10357206 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.Ophthalmic Res | PMID 37257422PMC10413800 | 2023 | 0.85 | While the record describes a randomized Phase 3b trial with a drug intervention and reports original results, the primary endpoint is the frequency of required change in ocular side effect management, which is a safety/quality-of-life endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or HR). The study was stopped early after a separate phase III trial showed no survival benefit, but this report does not present time-to-event data. | 待处理 |
| [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].Zh Nevrol Psikhiatr Im S S Korsakova | PMID 37315247无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phytotherapy (BNO 1045) of Acute Lower Uncomplicated Urinary Tract Infection in Women Normalizes Local Host Responses.Urol Int | PMID 37544300PMC10614491 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].Zh Nevrol Psikhiatr Im S S Korsakova | PMID 37560833无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.Am J Nephrol | PMID 37812931无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.Ann Med | PMID 37847999PMC10583612 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.J Prev Alzheimers Dis | PMID 37874099无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genotypic Effects of the TOMM40'523 Variant and APOE on Longitudinal Cognitive Change over 4 Years: The TOMMORROW Study.J Prev Alzheimers Dis | PMID 37874111PMC10734664 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Pathogenetic therapy of cognitive impairment: results of a multicenter placebo-controlled clinical trial of the efficacy and safety of Miladean].Zh Nevrol Psikhiatr Im S S Korsakova | PMID 37966441无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].Zh Nevrol Psikhiatr Im S S Korsakova | PMID 37994890无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701).Semin Oncol | PMID 36693773PMC10247389 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Endothelial dysfunction in ME/CFS patients.PLoS One | PMID 36730360PMC9894436 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil.Braz J Infect Dis | PMID 36750202PMC9978458 | 2023 | 0.45 | The study is a randomized phase 3 trial in pediatric ALL with a drug intervention (levofloxacin) and reports original results. However, the primary and secondary endpoints are safety and adverse events (CPE colonization, C. difficile diarrhea, febrile neutropenia), not time-to-event efficacy outcomes (e.g., OS, PFS, DFS). There is no mention of Kaplan-Meier analysis or hazard ratios for time-to-event endpoints. Therefore, it does not meet the inclusion criteria for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial.Pain Res Manag | PMID 36926379PMC10014159 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.PLoS One | PMID 36888640PMC9994755 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.PLoS One | PMID 36928877PMC10019690 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed dose combination of low dose pregabalin and duloxetine, or pregabalin monotherapy for neuropathic pain: A double-blind, randomized, parallel-group study.F1000Res | PMID 38618021PMC11016171 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine.Front Public Health | PMID 37181705PMC10169614 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.Front Immunol | PMID 37304255PMC10247956 | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result.Front Immunol | PMID 37404828PMC10315914 | 2023 | 0.45 | The record reports on a COVID-19 vaccine trial, not an oncology trial. It lacks a primary/key secondary time-to-event efficacy endpoint (like OS, PFS) and is not a drug intervention. Phase is combined Phase I/II, not Phase III/IIIb or definitive Phase II/III. | 待处理 |
| Prolonged continuous wound infusion of local anesthetic and steroid after major abdominal surgery to reduce opioid consumption: a randomized, double-blind trial.Minerva Anestesiol | PMID 37194239无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.Expert Rev Pharmacoecon Outcomes Res | PMID 37256558无 PMCID | 2023 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |